Avacta Share Discussion Threads

[mikro1] 02/1/2020 23:22

This share has the X factor in that it could go up 30 times if clinical trials go well and in that case it also hopes not to have to raise any more equity. As this dawns on more people the share price will likely soar even before the trial starts.

[bumpa33] 02/1/2020 13:53

Same to you Cmb - will be back at the screens properly when I’ve finished these two farm houses 🙄

[escapetohome] 02/1/2020 13:48

NICE start to the year, bottomed and trend slowly up.

[the stigologist] 02/1/2020 12:48

The way this is 'melting up' on no news in the New Year makes me wonder if there was some 'forced selling' or end of Quarter/Year/Decade window dressing going on with Institutions selling into year end 2019 ?

[the stigologist] 02/1/2020 12:14

Chart looking pretty interesting

[callmebwana] 31/12/2019 16:21

Bumpa33 and others, a very healthy and a prosperous New Year to you all, in whatever you are invested in.
ATB.

[ph1ts] 29/12/2019 12:20

I am sat on the sideline watching, after being burnt several times since 2011!!

[mikro1] 29/12/2019 06:42

I am still a patient holder. Despite my investment here being in the red at the moment I believe this will double or triple in the next few months on the back of pre trial excitement and good news flow

[escapetohome] 28/12/2019 17:11

Exciting for the company.

But not for shareholder unfortunately.

[lantanatony] 28/12/2019 16:36

Not many days left in this most exciting year for Avacta!!

[poacher45] 27/12/2019 10:33

Because it always promises and never delivers.

[escapetohome] 27/12/2019 10:11

So why is just about every bio active apart from poor old avct?

[escapetohome] 16/12/2019 17:50

C’mon mr predator.

Gobble this one up.

Sp too low too long.

[sunningdale1] 02/12/2019 08:56

For those interested in my previous post on Open Orphan (ORPH), November delivered some big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.

[bumpa33] 15/11/2019 18:54

Thanks wan, high risk/high reward - we will see, as you say ;)

[wanobi] 15/11/2019 13:18

best of luck with your projects Bumpa, I'm still invested here, still a LT believer, we shall see, cheers both, ATB Wan :-)

[bwana4] 15/11/2019 12:13

Yes,Bumpa. Though my holding here is not big at all. I know Bio-Tech Co,s can pay big time but do take a very long time.
I held RENE for quite sometime and sold it just before it went up !!
That is investing in Bio Tech Co,s.LOL.
Good to know you are OK.
ATB.

[bumpa33] 15/11/2019 11:53

Bwana - thank you, will be back in time - embroiled in some renovation projects and the vagaries of the Spanish legal system at the mo. Didn’t realise you were in this one. It’s been a rocky ride and the mkt is still valuing this as just another cash burning bio tech - which it might still turn out to be - but I think the mkt may have it wrong.

[nordic1958] 15/11/2019 10:06

Jefferies healthcare conference coming up shortly, Oncology will be the key topic.

[bwana4] 15/11/2019 09:21

Bumpa,good to see you posting.
Come back to Wan,BB. We all miss your input there.
I hope this comes good for all of us.
ATB and GLA,

[nordic1958] 14/11/2019 22:29

In particular one should focus when then the company in their latest presentation talks about new discussions.More deals to come I am sure

[mikro1] 14/11/2019 20:22

Thanks, but in my opinion AVCT is in a different league. I think AVCT has potential for at 10-20 times return in a 1-2 year timeframe if the human trials next year show it to be safe. And I think it is very likely to rise 2-3 times in the next few months in response to rising expectations/interest and good news flow

[sunningdale1] 14/11/2019 19:11

An exciting stock moving strongly in the right direction. For those interested in other growing pharma stocks big news this from Open Orphan as as Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.


This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

CEO Cathal Friel commented:
“When we completed the reverse takeover of Venn earlier this summer we promised shareholders that one of our key objectives would be to transform Venn into a profitable pharma services company. This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector. I look forward to announcing more positive news in due course.”

CEO Cathal Friel ensures this is not an exclusive offer but Venn have more to come in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

[nordic1958] 14/11/2019 11:29

Suspect with this sort of momentum and news flow, will attract other brokers.

[bumpa33] 14/11/2019 11:26

Hopefully they won’t have to come back to the mkt again, in which case it won’t matter. I wouldn’t be surprised if their desk had gone short, the mm there is an utter bell-end.